Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?
Salvatore Petta, Antonio Craxì – 6 February 2012
Correspondence
Korosh Khalili, Morris Sherman – 6 February 2012
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen‐positive chronic hepatitis B
Milan J. Sonneveld, Vincent Rijckborst, Stefan Zeuzem, E. Jenny Heathcote, Krzysztof Simon, Hakan Senturk, Suzan D. Pas, Bettina E. Hansen, Harry L.A. Janssen – 6 February 2012 – Peginterferon (PEG‐IFN) treatment of hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) results in HBeAg loss in 30% of patients, but clearance of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) from serum is less often achieved.
Drug‐related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma
Yan Zhao, Man Yang, Xingshun Qi, Guohong Han, Daiming Fan – 6 February 2012
Reply
P. Thomas Cherian, Nigel D. Heaton – 6 February 2012
Sinusoidal C4d deposits in liver allografts indicate an antibody‐mediated response: Diagnostic considerations in the evaluation of liver allografts
Tomasz Kozlowski, Kenneth Andreoni, John Schmitz, Paul Hideo Hayashi, Volker Nickeleit – 2 February 2012 – There is a paucity of data concerning the correlation of complement component 4d (C4d) staining in liver allografts and antibody‐mediated rejection. Data about the location and character of C4d deposits in native and allograft liver tissues are inconsistent.
Early viral load and recipient interleukin‐28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation
Ivo W. Graziadei, Heinz M. Zoller, Anna Schloegl, Karin Nachbaur, Karl‐Peter Pfeiffer, Walter Mark, Gregor Mikuz, Johann Pratschke, Raimund Margreiter, Wolfgang Vogel – 2 February 2012 – There have been few detailed studies of viral kinetics after liver transplantation (LT), and conflicting data have been reported on viral loads and the severity of recurrent hepatitis C virus (HCV) disease.
Living and dying well with end‐stage liver disease: Time for palliative care?
Kirsty Boyd, Barbara Kimbell, Scott Murray, John Iredale – 30 January 2012
Activation of cyclic adenosine monophosphate–dependent protein kinase a signaling prevents liver ischemia/reperfusion injury in mice
Haofeng Ji, Xiu‐da Shen, Yu Zhang, Feng Gao, Cynthia Y. Huang, William W. Chang, Coney Lee, Bibo Ke, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski – 30 January 2012 – Hepatic ischemia/reperfusion injury (IRI) occurs in multiple clinical settings, including liver transplantation. The cyclic adenosine monophosphate (cAMP)–dependent protein kinase A (PKA) pathway inhibits hepatocellular apoptosis and regulates toll‐like receptor 4–triggered inflammation responses in vitro.
Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma
Sarwa Darwish Murad, W. Ray Kim, Terry Therneau, Gregory J. Gores, Charles B. Rosen, James A. Martenson, Steven R. Alberts, Julie K. Heimbach – 30 January 2012 – We have previously reported excellent outcomes with liver transplantation for selected patients with early‐stage perihilar cholangiocarcinoma (CCA) following neoadjuvant chemoradiotherapy. Our aim was to identify predictors of dropout before transplantation and predictors of cancer recurrence after transplantation.